These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 28423693)

  • 1. Enhanced anti-tumor therapeutic efficacy of DNA vaccine by fusing the E7 gene to BAFF in treating human papillomavirus-associated cancer.
    Wu CC; Wu FC; Hsu YT; Hsiao YC; Yang YC; Chang CA; Chang CL
    Oncotarget; 2017 May; 8(20):33024-33036. PubMed ID: 28423693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of therapeutic DNA vaccine potency by melatonin through inhibiting VEGF expression and induction of antitumor immunity mediated by CD8+ T cells.
    Baghban Rahimi S; Mohebbi A; Vakilzadeh G; Biglari P; Razeghi Jahromi S; Mohebi SR; Shirian S; Gorji A; Ghaemi A
    Arch Virol; 2018 Mar; 163(3):587-597. PubMed ID: 29149434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD4+ TH1 cells generated by Ii-PADRE DNA at prime phase are important to induce effectors and memory CD8+ T cells.
    Park JY; Jin DH; Lee CM; Jang MJ; Lee SY; Shin HS; Chung YH; Kim KY; Kim SS; Lee WB; Shin YK; Lee WJ; Park YM; Kim D
    J Immunother; 2010 Jun; 33(5):510-22. PubMed ID: 20463596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of DNA vaccine potency by linkage of antigen gene to a gene encoding the extracellular domain of Fms-like tyrosine kinase 3-ligand.
    Hung CF; Hsu KF; Cheng WF; Chai CY; He L; Ling M; Wu TC
    Cancer Res; 2001 Feb; 61(3):1080-8. PubMed ID: 11221836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Noncarrier naked antigen-specific DNA vaccine generates potent antigen-specific immunologic responses and antitumor effects.
    Chen CA; Chang MC; Sun WZ; Chen YL; Chiang YC; Hsieh CY; Chen SM; Hsiao PN; Cheng WF
    Gene Ther; 2009 Jun; 16(6):776-87. PubMed ID: 19357714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel recombinant protein vaccine containing the different E7 proteins of the HPV16, 18, 6, 11 E7 linked to the HIV-1 Tat (47-57) improve cytotoxic immune responses.
    Mousavi T; Valadan R; Rafiei A; Abbasi A; Haghshenas MR
    Biotechnol Lett; 2021 Sep; 43(9):1933-1944. PubMed ID: 34313864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Linkage of modified human papillomavirus type 16 E7 to CD40 ligand enhances specific CD8+ T-lymphocyte induction and anti-tumour activity of DNA vaccine].
    Wang QY; Xu YF; Fan DS; Peng QL; Zhang T; Xu XM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Oct; 29(5):584-91. PubMed ID: 18051710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel self-assembled nanoparticle vaccine with HIV-1 Tat₄₉₋₅₇/HPV16 E7₄₉₋₅₇ fusion peptide and GM-CSF DNA elicits potent and prolonged CD8⁺ T cell-dependent anti-tumor immunity in mice.
    Tang J; Yin R; Tian Y; Huang Z; Shi J; Fu X; Wang L; Wu Y; Hao F; Ni B
    Vaccine; 2012 Feb; 30(6):1071-82. PubMed ID: 22178528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful therapeutic vaccination with integrase defective lentiviral vector expressing nononcogenic human papillomavirus E7 protein.
    Grasso F; Negri DR; Mochi S; Rossi A; Cesolini A; Giovannelli A; Chiantore MV; Leone P; Giorgi C; Cara A
    Int J Cancer; 2013 Jan; 132(2):335-44. PubMed ID: 22700466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of HLA-A2-restricted HPV-16 E7-specific CD8(+) T-cell immune responses induced by DNA vaccines in HLA-A2 transgenic mice.
    Peng S; Trimble C; He L; Tsai YC; Lin CT; Boyd DA; Pardoll D; Hung CF; Wu TC
    Gene Ther; 2006 Jan; 13(1):67-77. PubMed ID: 16107858
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhancing DNA vaccine potency by co-administration of xenogenic MHC class-I DNA.
    Kang TH; Chung JY; Monie A; Pai SI; Hung CF; Wu TC
    Gene Ther; 2010 Apr; 17(4):531-40. PubMed ID: 19940864
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of HPV DNA vaccines employing intracellular targeting strategies.
    Kim JW; Hung CF; Juang J; He L; Kim TW; Armstrong DK; Pai SI; Chen PJ; Lin CT; Boyd DA; Wu TC
    Gene Ther; 2004 Jun; 11(12):1011-8. PubMed ID: 14985791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Histone deacetylase inhibitor AR-42 enhances E7-specific CD8⁺ T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination.
    Lee SY; Huang Z; Kang TH; Soong RS; Knoff J; Axenfeld E; Wang C; Alvarez RD; Chen CS; Hung CF; Wu TC
    J Mol Med (Berl); 2013 Oct; 91(10):1221-31. PubMed ID: 23715898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancing major histocompatibility complex class I antigen presentation by targeting antigen to centrosomes.
    Hung CF; Cheng WF; He L; Ling M; Juang J; Lin CT; Wu TC
    Cancer Res; 2003 May; 63(10):2393-8. PubMed ID: 12750257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimal induction of HPV DNA vaccine-induced CD8+ T cell responses and therapeutic antitumor effect by antigen engineering and electroporation.
    Seo SH; Jin HT; Park SH; Youn JI; Sung YC
    Vaccine; 2009 Sep; 27(42):5906-12. PubMed ID: 19651174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site.
    Lamikanra A; Pan ZK; Isaacs SN; Wu TC; Paterson Y
    J Virol; 2001 Oct; 75(20):9654-64. PubMed ID: 11559797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a DNA vaccine targeting human papillomavirus type 16 oncoprotein E6.
    Peng S; Ji H; Trimble C; He L; Tsai YC; Yeatermeyer J; Boyd DA; Hung CF; Wu TC
    J Virol; 2004 Aug; 78(16):8468-76. PubMed ID: 15280455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Different domains of glycoprotein 96 influence HPV16 E7 DNA vaccine potency via electroporation mediated delivery in tumor mice model.
    Daemi A; Bolhassani A; Rafati S; Zahedifard F; Hosseinzadeh S; Doustdari F
    Immunol Lett; 2012 Dec; 148(2):117-25. PubMed ID: 23085605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract.
    Sun YY; Peng S; Han L; Qiu J; Song L; Tsai Y; Yang B; Roden RB; Trimble CL; Hung CF; Wu TC
    Clin Cancer Res; 2016 Feb; 22(3):657-69. PubMed ID: 26420854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic effect of programmed cell death protein 1 blockade and secondary lymphoid tissue chemokine in the induction of anti-tumor immunity by a therapeutic cancer vaccine.
    Moeini S; Saeidi M; Fotouhi F; Mondanizadeh M; Shirian S; Mohebi A; Gorji A; Ghaemi A
    Arch Virol; 2017 Feb; 162(2):333-346. PubMed ID: 27699512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.